Raphael Pharmaceutical Inc. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Raphael Pharmaceutical Inc. (RAPH) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of -$269.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-03-31
- Raphael Pharmaceutical Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2025 was -$269.00K.
- Raphael Pharmaceutical Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2024 was -$319.00K.
- Raphael Pharmaceutical Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2023 was -$282.00K.
- Raphael Pharmaceutical Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2022 was -$705.00K.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$269.00K 10-K · filed 2026-03-31 | |
| 2024-12-31 | -$319.00K 10-K · filed 2026-03-31 | |
| 2023-12-31 | -$282.00K 10-K · filed 2025-03-31 | -$270.00K 10-K · filed 2024-03-28 |
| 2022-12-31 | -$705.00K 10-K · filed 2024-03-28 | |
| 2021-12-31 | -$341.00K 10-K/A · filed 2023-05-25 | |
| 2020-12-31 | -$151.00K 10-K · filed 2022-03-30 |